HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2007.01.067v1 49/17/1753    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Davidson, M. H. Articles by Robinson, J. G. Search for Related Content PubMed Articles by Davidson, M. H. Articles by Robinson, J. G.

STATE-OF-THE-ART PAPER

Safety of Aggressive Lipid Management

Michael H. Davidson, MD, FACC^_*,_* and Jennifer G. Robinson, MD, MPH

^_* Radiant Research, Rush University Medical Center, Chicago, Illinois
University of Iowa, Iowa City, Iowa

Manuscript received April 6, 2006; revised manuscript received January 16, 2007, accepted January 22, 2007.

^_* Reprint requests and correspondence: Dr. Michael H. Davidson, Radiant Research, Rush Medical College, Rush University Medical Center, 1725 West Harrison Street, Suite 1159, Chicago, Illinois (Email: michaeldavidson{at}radiantresearch.com).

Data from recent clinical trials of high- versus moderate-dose statin therapy support the recommendation to achieve a low-density lipoprotein (LDL) <100 mg/dl in high-risk patients and reveal that many patients will require a high-dose statin to achieve this goal. Overall, low rates of serious musculoskeletal (<0.6%) and hepatic (<1.3%) toxicity have been observed with high-dose statin therapy. In the long-term trials, atorvastatin 80 mg had higher rates of persistent transaminase elevations but rates of myopathy and rhabdomyolysis similar to lower doses of statins. The rate of myopathy and rhabdomyolysis for simvastatin 80 mg, although still low, was about 4x higher than for atorvastatin 80 mg and lower doses of statin. A similar margin of safety would be expected in properly selected patients with characteristics similar to those who participated in the clinical trials. High-dose statin therapy or combination therapy will be required for the large majority of very high-risk patients to achieve the optional LDL goal of <70 mg/dl. While the combination of ezetimibe, bile-acid sequestering agents, niacin, and fenofibrate with moderate dose statins appears to be reasonably safe, the long-term safety of combination with high-dose statins remains to be established. In order to optimize patient outcomes, clinicians should be aware of specific patient characteristics, such as advancing age, gender, body mass index, or glomerular filtration rate, which predict muscle and hepatic statin toxicity.

Abbreviations and Acronyms   CHD = coronary heart disease   CI = confidence interval   CK = creatine kinase   CYP = cytochrome   FDA = Food and Drug Administration   HDL = high-density lipoprotein   HR = hazard ratio   LDL = low-density lipoprotein   NCEP = National Cholesterol Education Program Adult Treatment Panel   ULN = upper limit of normal

This article has been cited by other articles:

				Which Statin? Obstet. Gynecol., September 1, 2008; 112(3): 696 - 698. [Full Text] [PDF]

				J Armitage Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia Heart, May 1, 2008; 94(5): 643 - 645. [Full Text] [PDF]